Аннотация:
Systemic vasculitis is a heterogeneous group of inflammatory diseases, which are classified according to the diameter of the affected vessels. The treatment of systemic vasculitis is no longer empirical, because of increasing number of randomized clinical trials in this field. In recent years, there was a trend to limit the cumulative dose of glucocorticosteroids and immunosuppressive drugs, partially through biological drugs usage. However, biologic therapy is not always superior to combination of glucocorticosteroids and cytotoxic drugs. The efficacy of different biologic drugs varies in patients with different forms of systemic vasculitis, which creates the ground for personalized therapy of these diseases. Another serious problem is the absence of strict criteria to immunosuppressive therapy intensification, especially in vasculitis, affecting large vessels, due to the lack of reliable laboratory markers of disease activity. The article reviews modern approaches to the treatment of
Ключевые слова:
ANCA-associated vasculitis; Clinical trials; HCV-associated cryoglobulinemia; Large vessel vasculitis; Ongoing study; Takayasu`s arteritis
human; randomized controlled trial (topic); systemic vasculitis; Humans; Randomized Controlled Trials as Topic; Systemic Vasculitis
Новиков П. И. Павел Игоревич 1982-
Зыкова А. С. Анастасия Сергеевна 1991-
Моисеев С. В. Сергей Валентинович 1960-
Novikov P. I. Pavel Igorevich 1982-
Zy'kova A. S. Anastasiya Sergeevna 1991-
Moiseev S. V. Sergej Valentinovich 1960-
The modern therapy of systemic vasculitides: Perspectives and challenges
Текст визуальный непосредственный
Терапевтический архив
Медицинское маркетинговое агентство "МедиаМедика"
Т. 90, Вып. 1 С. 76-85
2018
Статья
ANCA-associated vasculitis Clinical trials HCV-associated cryoglobulinemia Large vessel vasculitis Ongoing study Takayasu`s arteritis
human randomized controlled trial (topic) systemic vasculitis Humans Randomized Controlled Trials as Topic Systemic Vasculitis
Systemic vasculitis is a heterogeneous group of inflammatory diseases, which are classified according to the diameter of the affected vessels. The treatment of systemic vasculitis is no longer empirical, because of increasing number of randomized clinical trials in this field. In recent years, there was a trend to limit the cumulative dose of glucocorticosteroids and immunosuppressive drugs, partially through biological drugs usage. However, biologic therapy is not always superior to combination of glucocorticosteroids and cytotoxic drugs. The efficacy of different biologic drugs varies in patients with different forms of systemic vasculitis, which creates the ground for personalized therapy of these diseases. Another serious problem is the absence of strict criteria to immunosuppressive therapy intensification, especially in vasculitis, affecting large vessels, due to the lack of reliable laboratory markers of disease activity. The article reviews modern approaches to the treatment of